Reappraisal and perspectives of clinical drug–drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus

References

• Ahr HJ, Boberg M, Brendel E, et al. (1997). Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 47:734–45
   PubMed Web of Science ®Google Scholar
• Balan G, Timmins P, Greene DS, et al. (2001). In vitro–in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. J Pharm Sci 90:1176–85
   PubMed Web of Science ®Google Scholar
• Benet LZ. (2009). The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol Pharm 6:1631–43
   PubMed Web of Science ®Google Scholar
• Blix HS, Viktil KK, Moger TA, Reikvam A. (2010). Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharm Pract (Granada) 8:50–5
   PubMedGoogle Scholar
• Bollen M, Vandebroeck A, Stalmans W. (1988). 1-Deoxynojirimycin and related compounds inhibit glycogenolysis in the liver without affecting the concentration of phosphorylase A. Biochem Pharmacol 37:905–9
   PubMed Web of Science ®Google Scholar
• Campbell LK, Baker DE, Campbell RK. (2000). Miglitol: assessment of its role in the treatment of patients with diabetes mellitus. Ann Pharmacother 34:1291–301
   PubMed Web of Science ®Google Scholar
• Ceriello A. (2005). Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54:1–7
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Hunt JA, et al. (1994). The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 121:928–35
   PubMed Web of Science ®Google Scholar
• Clissold SP, Edwards C. (1988). Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35:214–43
   PubMed Web of Science ®Google Scholar
• Cohen E, Almog S, Staruvin D, et al. (2002). Do therapeutic doses of acarbose alter the pharmacokinetics of digoxin? Isr Med Assoc J 4:772–5
   PubMed Web of Science ®Google Scholar
• Dabhi AS, Bhatt NR, Shah MJ. (2013). Voglibose: an alpha glucosidase inhibitor. J Clin Diagn Res 7:3023–3027
   PubMedGoogle Scholar
• Enç FY, Imeryüz N, Akin L, et al. (2001). Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol 281:G752–63.
   PubMed Web of Science ®Google Scholar
• Fuder H, Kleist P, Birkel M, et al. (1997). The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. Eur J Clin Pharmacol 53:153–7
   PubMed Web of Science ®Google Scholar
• Gerard J, Lefebvre PJ, Luyckx AS. (1984). Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics. Eur J Clin Pharmacol 27:233–6
   PubMed Web of Science ®Google Scholar
• Gleiter CH, Schreeb KH, Freudenthaler S, et al. (1999). Lack of interaction between thioctic acid, glibenclamide and acarbose. Br J Clin Pharmacol 48:819–25
   PubMed Web of Science ®Google Scholar
• Glyset. (2012). Glyset® (miglitol) tablets, Prescribing information, Bayer HealthCare Pharmaceuticals Inc., Revised August 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020682s010lbl.pdf [last accessed 24 Aug 2016]
   Google Scholar
• Göke B, Fuder H, Wieckhorst G, et al. (1995). Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 56:493–501
   PubMed Web of Science ®Google Scholar
• Goyani V, Rathod R, Dash RP, et al. (2013). Simultaneous quantification of aliskiren, valsartan and sitagliptin by LC with fluorescence detection: evidence of pharmacokinetic interaction in rats. Chromatographia 76:515–21
   Web of Science ®Google Scholar
• Guidance for Industry, Diabetes Mellitus: developing drugs and therapeutic biologics for treatment and prevention. (2008). Rockville, MD: U.S. Department of Health and Human Services, US FDA (Draft Guidance)
   Google Scholar
• Guidance for Industry, Drug interaction studies-Study design, data analysis, implications for dosing, and labeling recommendations. (2012). Rockville, MD: U.S. Department of Health and Human Services, US FDA (Draft Guidance)
   Google Scholar
• Hanefeld M, Schaper F. (2008). Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 6:153–63
   PubMedGoogle Scholar
• Hanefeld M, Schaper F. (2007). The role of alpha-glucosidase inhibitors (acarbose). In: Pharmacotherapy of diabetes: new developments. diabetes: endocrinology. Part 2. US: Springer
   Google Scholar
• He L. (1998). Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 6:132–45
   Google Scholar
• Hillebrand I, Graefe KH, Bischoff H, et al. (1982). Serum digoxin and propranolol levels during acarbose treatment. Int Congr Ser 594:244–6
   Google Scholar
• Hisaka A, Ohno Y, Yamamoto T, et al. (2010). Prediction of pharmacokinetic drug–drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacol Ther 125:230–48
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Spengler M. (1994). Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 17:561–6
   PubMed Web of Science ®Google Scholar
• Holstein A, Beil W. (2009). Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol 5:225–41
   PubMed Web of Science ®Google Scholar
• Available from: http://www.diabetes.org/advocacy/news-events/cost-of-diabetes.html?referrer=https://www.google.com/ [last accessed 11 August 2016]
   Google Scholar
• Available from: http://www.who.int/mediacentre/factsheets/fs312/en/ [last accessed 11 August 2016]
   Google Scholar
• Hussain SA, Kurji HAH, Ghareeb MM, Abdulrazzaq MH. (2012). Effect of acarbose on the bioavailability and pharmacokinetics of metronidazole in healthy and diabetic subjects. Br J Pharm Res 2:41–9
   Google Scholar
• Imamura A, Kusunoki M, Ueda S, et al. (2013). Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes. Diabetes Ther 4:41–9
   PubMed Web of Science ®Google Scholar
• Johnston PS, Lebovitz HE, Coniff RF, et al. (1998). Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 83:1515–22
   PubMed Web of Science ®Google Scholar
• Jonas D, Scoyoc EV, Gerrald K, et al. 2011. Drug class review: newer diabetes medications, TZDs, and combinations. Portland (OR): Oregon Health & Science University
   Google Scholar
• Joshi SR, Standl E, Tong N, et al. (2015). Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin Pharmacother 16:1959–81
   PubMed Web of Science ®Google Scholar
• Kaku K. (2014). Efficacy of voglibose in type 2 diabetes. Expert Opin Pharmacother 15:1181–90
   PubMed Web of Science ®Google Scholar
• Kasahara N, Fukase H, Ohba Y, et al. (2015). A pharmacokinetic/pharmacodynamic drug–drug interaction study of tofogliflozin (a new SGLT2 inhibitor) and selected anti-type 2 diabetes mellitus drugs. Drug Res (Stuttg) 66:74–81
   PubMed Web of Science ®Google Scholar
• Kim HS, Oh M, Kim EJ, et al. (2014). Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects. Int J Clin Pharmacol Ther 52:1005–11
   PubMed Web of Science ®Google Scholar
• Kim S, Jang IJ, Shin D, et al. (2014). Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug–drug interaction potential between both drugs in healthy adult male subjects. J Clin Pharm Ther 39:424–31
   PubMed Web of Science ®Google Scholar
• Klatt S, Fromm MF, König J. (2011). Transporter-mediated drug–drug interactions with oral antidiabetic drugs. Pharmaceutics 3:680–705
   PubMedGoogle Scholar
• Kleist P, Ehrlich A, Suzuki Y, et al. (1997). Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide. Eur J Clin Pharmacol 53:149–52
   PubMed Web of Science ®Google Scholar
• Kleist P, Suzuki Y, Thomsen T, et al. (1997). Voglibose has no effect on the pharmacokinetics of hydrochlorothiazide. Eur J Clin Pharmacol 54:273–4
   Web of Science ®Google Scholar
• Kumar S, Narwal S, Kumar V, et al. (2011). α-glucosidase inhibitors from plants: a natural approach to treat diabetes. Pharmacogn Rev 5:19–29
   PubMedGoogle Scholar
• Kusumoto M, Ueno K, Fujimura Y, et al. (1999). Lack of kinetic interaction between digoxin and voglibose. Eur J Clin Pharmacol 55:79–80
   PubMed Web of Science ®Google Scholar
• Luna B, Feinglos MN. (2001). Oral agents in the management of type 2 diabetes mellitus. Am Fam Phys 63:1747–56
   PubMed Web of Science ®Google Scholar
• Maitra A, Abbas AK. (2005). Endocrine system. In: Kumar V, Fausto N, Abbas AK, eds. Robbins and Cotran pathologic basis of disease. 7th ed. Philadelphia: Saunders
   Google Scholar
• Mikada A, Narita T, Yokoyama H, et al. (2014). Effects of miglitol, sitagliptin, and initial combination therapy with both on plasma incretin responses to a mixed meal and visceral fat in over-weight Japanese patients with type 2 diabetes. “the MASTER randomized, controlled trial”. Diabetes Res Clin Pract 106:538–47
   PubMed Web of Science ®Google Scholar
• Miller AK, Inglis AM, Culkin KT, et al. (2001). The effect of acarbose on the pharmacokinetics of rosiglitazone. Eur J Clin Pharmacol 57:105–9
   PubMed Web of Science ®Google Scholar
• Miura T, Ueno K, Tanaka K, et al. (1998). Impairment of absorption of digoxin by acarbose. J Clin Pharmacol 38:654–7
   PubMed Web of Science ®Google Scholar
• Morreale AP, Janetzky K. (1997). Probable interaction of warfarin and acarbose. Am J Health Syst Pharm 54:1551–2
   PubMed Web of Science ®Google Scholar
• Muller FO, Hillebrand I. (1986). Acarbose (BAY g 5421) kinetics in healthy volunteers. Acta Pharmacol Toxicol 59:303
   PubMedGoogle Scholar
• Olokoba AB, Obateru OA, Olokoba LB. (2012). Type 2 diabetes mellitus: a review of current trends. Oman Med J 27:269–73
   PubMedGoogle Scholar
• Ono Y, Kamoshima H, Nakamura A, et al. (2014). Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination. Expert Opin Pharmacother 15:1785–95
   PubMed Web of Science ®Google Scholar
• Pang KS, Maeng HJ, Fan J. (2009). Interplay of transporters and enzymes in drug and metabolite processing. Mol Pharm 6:1734–55
   PubMed Web of Science ®Google Scholar
• Putter J, Keup U, Krause HP, et al. (1981). Pharmacokinetics of acarbose. In: Cretzfeldt W, ed. Proceedings of First International Symposium on Acarbose. Montreux: Excerpta Medica
   Google Scholar
• Putter J. (1980). Studies on the pharmacokinetics of acarbose in humans. In: Brodeck U, ed. Enzyme inhibitors. Weinheim: Verlag Chemie
   Google Scholar
• Richardt D, Rosmarin C, Havlik I, et al. (1997). No effect of miglitol on the oral bioavailability of single-dose phenytoin in healthy males. Clin Drug Invest 13:171–4
   Web of Science ®Google Scholar
• Rodger NW, Chiasson JL, Josse RG, et al. (1995). Clinical experience with acarbose: results of a Canadian multicentre study. Clin Invest Med 18:318–24
   PubMed Web of Science ®Google Scholar
• Saboo B, Reddy GC, Juneja S, et al. (2015). Effectiveness and safety of fixed dose combination of acarbose/metformin in Indian Type 2 diabetes patients: results from observational GLOBE Study. Indian J Endocrinol Metab 19:129–35
   PubMedGoogle Scholar
• Salvatore T, Giugliano D. (1996). Pharmacokinetic–pharmacodynamic relationships of acarbose. Clin Pharmacokinet 30:94–106
   PubMed Web of Science ®Google Scholar
• Sasaki T, Seino Y, Fukatsu A, et al. (2015). Absence of drug–drug interactions between luseogliflozin, a sodium-glucose co-transporter-2 inhibitor, and various oral antidiabetic drugs in healthy Japanese males. Adv Ther 32:404–17
   PubMed Web of Science ®Google Scholar
• Schall R, Müller FO, Hundt HK, et al. (1996). Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Arzneimittelforschung 46:41–6
   PubMed Web of Science ®Google Scholar
• Scheen AJ, de Magalhaes AC, Salvatore T, Lefebvre PJ. (1994). Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 24:50–4
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Lefèbvre PJ. (2002). Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents. Diabetes Care 25:247–8
   PubMed Web of Science ®Google Scholar
• Sels JP, Huijberts MS, Wolffenbuttel BH. (1999). Miglitol, a new alpha-glucosidase inhibitor. Expert Opin Pharmacother 1:149–56
   PubMedGoogle Scholar
• Serrano JS, Jiménez CM, Serrano MI, et al. (1996). A possible interaction of potential clinical interest between digoxin and acarbose. Clin Pharmacol Ther 60:589–92
   PubMed Web of Science ®Google Scholar
• van de Laar FA, Lucassen PL, Akkermans RP, et al. (2005). Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 28:154–63
   PubMed Web of Science ®Google Scholar
• van de Laar FA. (2008). Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vasc Health Risk Manag 4:1189–95
   PubMedGoogle Scholar
• Varma MV, El-Kattan AF. (2016). Transporter–enzyme interplay: deconvoluting effects of hepatic transporters and enzymes on drug disposition using static and dynamic mechanistic models. J Clin Pharmacol 56:S99–S109
   PubMed Web of Science ®Google Scholar
• Voglibose. (2016). Voglibose® dispersible tablets. Summary of product characteristics. Available from: www.biocon.com/docs/prescribing_information/diabetology/volicose_pi.pdf [last accessed 26 August 2016]
   Google Scholar
• Woerle HJ, Neumann C, Zschau S, et al. (2007). Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 77:280–5
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Saji T, Mita S, et al. (2013). Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. Int J Clin Pharmacol Ther 51:641–51
   PubMed Web of Science ®Google Scholar
• Yang W, Lin L, Qi J. (2001). The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab 17:131–6
   Google Scholar